Nicole Kounalakis, MD
Surgical Oncology · Atlanta, GANPI 1902003684
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,140 of the $13,927 with a category attached, or 87.2%. Merck accounts for 72.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $9,721 and has fallen 98.4% since, to $154 in 2025. Among surgical oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $994.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10K
- E.r. Squibb & Sons, L.L.C.$4K
- Iovance Biotherapeutics, Inc.$154
- Aadi Bioscience, Inc.$116
Across 12 payments — averaging $27,632 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$332K
What the payments were for
- Consulting fees$12,14087%
- Travel & lodging$1,1869%
- Food & beverage$6014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $10,056 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,600 |
| Iovance Biotherapeutics, Inc. | 1 | $154 |
| Aadi Bioscience, Inc. | 1 | $116 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,927 in reported general payments places this provider in the 90th percentile of 43 surgical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $101 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $75 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Atlanta
- Eddie AbdallaAtlanta$34K
- Atuhani BurnettAtlanta$23K
- Barry RosemanAtlanta$10K
- David KoobyAtlanta$6K
- Salila HashmiAtlanta$6K
- Neil SaundersAtlanta$5K
- Meredith MasonAtlanta$5K
- Clara FarleyAtlanta$4K
- Olivia ChengAtlanta$3K
- Laurel BarnesAtlanta$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.